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PlacentaAlterations in expression of the imprinted gene PHLDA2 are linked to low birth weight in both humans and
the mouse. However birth weight is a summary measure of fetal growth and provides little information on
the growth rate of the fetus in early and late pregnancy. To examine the relation of PHLDA2 expression
with rates of fetal growth and explore associations with the infant's body composition in early childhood,
we measured PHLDA2 mRNA levels in the term placenta of 102 infants whose mothers were participating
in the Southampton Women's Survey (SWS). Higher PHLDA2 expression was associated with a lower fetal
femur growth velocity between 19 and 34 weeks gestation. In addition, higher placental PHLDA2 gene
expression was associated with a lower child's bone mineral content at four years of age, measured using
dual-energy X-ray absorptiometry. The results suggest that placental PHLDA2 may provide a biomarker for
suboptimal skeletal growth in pregnancies uncomplicated by overt fetal growth restriction.
© 2011 Elsevier Inc. Open access under CC BY license.Introduction
The most common cause of low birth weight (LBW) at term in
Western societies is placental insufﬁciency [1]. LBW infants have
not attained their growth potential (reviewed in [2]) but in addition
birth weight is an important indicator of both short and long term
health. LBW infants have a 10–20 fold increased risk of dying in the
perinatal period [3] and are at increased risk of developing chronic
diseases including type 2 diabetes, hypertension and heart disease
in later life (discussed in [4,5]). Postnatal ‘catch up’ growth is ob-
served in 70–90% of LBW infants and is generally complete by two
years of age [6,7]. It is now widely accepted that human fetuses areterests, direct or indirect, that
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 license.able to respond to a limited supply of nutrients by changing their
physiology and metabolism but this predisposes to chronic disease
in later life [8]. There is now extensive data from animal models to
support this hypothesis [9–14].
Elevated expression of the human PHLDA2 gene has been reported
in the term placentas of LBW infants in two independent studies
[15,16]. In a study of routine, ultrasound-dated pregnancies, higher
placental PHLDA2 expression was also shown to correlate with
lower birth weight [17]. PHLDA2 belongs to a family of imprinted
genes expressed from only the maternally-inherited allele [18]. In
humans, PHLDA2 is expressed primarily in the placenta in the villous
cytotrophoblast until term [19]. Similarly, expression in the mouse is
predominantly placental [18,20,21]. In mice PHLDA2 gene knockout
results in placentomegaly with an expansion of the junctional zone
but has no apparent consequence for fetal weight, fetal viability
or adult health [22]. In contrast, mice genetically engineered to
over-express PHLDA2 show a reduced placental weight and there is
reduced fetal growth late in gestation, suggesting placental insufﬁ-
ciency [23,24]. Data from the mouse model suggest that excess
expression of PHLDA2 in the placenta of human LBW infants is not
merely a consequence of a dysfunctional placenta but contributes to
the reduction in growth. Determining placental PHLDA2 expression
may therefore help identify infants who have not reached their
338 R.M. Lewis et al. / Bone 50 (2012) 337–342full growth potential. Distinguishing these infants may allow targeted
interventions early in life to optimize adult health.
In this study, we examined PHLDA2 expression in placentas of 102
infants born to mothers participating in the Southampton Women's
Survey for whom there is detailed information about fetal growth
and placental weight at term [25]. In addition to measurements of
fetal growth velocity, we correlated placental expression of PHLDA2
with the infant's anthropometry, bone mass and body composition
at birth (measured by dual-energy X-ray absorptiometry (DXA))
and, where data were available, bone mass and body composition
in early childhood. We found no signiﬁcant relationship between
PHLDA2 expression and birth weight in this cohort, but there were
relationships between higher placental PHLDA2 expression and
lower femur growth rate between 19 and 34 weeks of gestation and
lower bone mineral content at 4 years.
Subjects and methods
Cohort
Details of the Southampton Women's Survey (SWS) have been
published previously [25]. In a group of pregnancies the placenta
was collected within 30 min of delivery. The weight of the placenta
was measured after removing any obvious blood clots, cutting the
umbilical cord ﬂush with its insertion into the placenta, trimming
away surrounding membranes and removing the amnion from
the basal plate. To ensure that samples collected were representative
of the placenta as a whole, 5 villous tissue samples were selected
using a stratiﬁed random sampling method and stored at −80 °C.
For this study, we selected 102 placentas (from 300 collected in
total) based on availability of neonatal DXA data.
Fetal ultrasonography
In 58 pregnancies, measures of fetal size and growth velocity were
available from ultrasound scans performed by a research sonographer
at 19 and 34 weeks gestation. Using a high resolution ultrasound sys-
tem (Kretz Voluson 730), head circumference (HC) was obtained
using an ellipse superimposed on a static scan image of the horizontal
plane at the level of the thalamus and the cavum septi pellucidi [26].
Abdominal circumference (AC) was also similarly measured using a
transverse section of the fetal abdomen at the level of the fetal stom-
ach and where a short section of umbilical vein can be identiﬁed.
Femur length (FL) was measured in longitudinal section by placing
the linear calipers at the ends of the diaphysis, with the femur hori-
zontally positioned in the scan plane [26]. Three measurements
were made of each parameter and the mean used in the statistical
analysis [27]. Precision of the measurements was assessed by repli-
cate examinations in 50 pregnancies at both 19 and 34 weeks. The
coefﬁcient of variation for triplicate linear measurements was 0.6%
at 19 weeks and 0.4% at 34 weeks [27]. For elliptical measurements
the values were 4.4% at 19 and 3.2% at 34 weeks.
Postnatal measurements
The infant's gestational age at birth was calculated from the date
of the mother's last menstrual period (LMP) and conﬁrmed by ultra-
sonography, or adjusted by an early dating scan if the LMP was
unsure. Shortly after delivery, research midwives recorded neonatal
anthropometric measures (including birth weight, head, abdominal
and mid-upper arm circumferences and crown–heel length).
A subset of 42 mothers and children were invited to visit the Oste-
oporosis Centre at Southampton General Hospital for assessment
of bone mass when the child was 4 years old. At this visit written in-
formed consent for the DXA scan was obtained from the mother or
father. The child's height (using a Leicester height measurer) andweight (in underpants only, using calibrated digital scales (Seca
Ltd.)) were measured. A whole body DXA scan was obtained, using
a Hologic Discovery instrument (Hologic Inc., Bedford, MA, USA). To
encourage compliance, a sheet with appropriate colored cartoons
was laid on the couch ﬁrst; to help reduce movement artifact, the
children were shown a suitable DVD cartoon. The total radiation
dose for the scans was 4.7 microsieverts for whole body measure-
ment (pediatric scan mode). The manufacturer's coefﬁcient of varia-
tion (CV) for the instrument was 0.75% for whole body bone
mineral density, and the experimental CV when a spine phantom
was repeatedly scanned in the same position 16 times was 0.68%.
RNA extraction and cDNA synthesis
For each placenta 5 snap frozen samples were pooled and pow-
dered in a frozen tissue press. Total RNA was extracted from 30 mg
powdered placental tissue using the RNeasy ﬁbrous tissue RNA isola-
tion mini kit (Qiagen, UK) according to the manufacturer's instruc-
tions. The integrity of total RNA was conﬁrmed by visualization of
ribosomal bands with ethidium bromide under ultra violet illumina-
tion by agarose gel electrophoresis, in 1× TAE buffer.
Total RNA (0.2 μg) was reverse transcribed with 0.5 μg random
hexamer primer, 200 units M-MLV reverse transcriptase, 25 units re-
combinant RNasin ribonuclease inhibitor and 0.5 mM each of dATP,
dCTP, dGTP and dTTP in a ﬁnal reaction volume of 25 μl in 1×
MMLV reaction buffer (Promega, Wisconsin, USA). All 102 samples
were produced in one batch to reduce variation.
Probe and primer design
Oligonucleotide probes and primers were designed using the
Roche ProbeFinder version 2.45 for human. Probes were supplied by
Roche from the human universal probe library and primers were syn-
thesized by Eurogentec (Seraing, Belgium). PHLDA2: Forward 5′-
atcacttggccagtttgctt-3′, Reverse 5′-gactggatgagggtgtcctg-3′, probe
#3. Control genes (YWHAZ, UBC and TOP1) were selected using the
geNormTM human Housekeeping Gene Selection Kit (Primer Design
Limited, Southampton UK).
Real-time PCR using a Roche light-cycler 480. For Roche universal
probe library probes the cycle parameters were 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. For primer
design Perfect Probes the cycle parameters were 95 °C for 10 min,
followed by 40 cycles of 95 °C for 10 s and 60 °C and 72 °C for 15 s.
Intra-assay CV's for each gene were 5–8%. Each of the 102 samples
was run on the same plate in triplicate. All mRNA levels are presented
relative to the geometric mean of the three control genes.
PHLDA2 expression levels were quantiﬁed by Real-time PCR
(QPCR) against three reference genes: tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta polypeptide
(YWHAZ), ubiquitin C (UBC) and topoisomerase (TOP1) [28].
Statistics
Summary data are presented as mean (SD) or median (inter-quar-
tile range) depending on whether or not the data were normally dis-
tributed. Variables not normally distributed were transformed
logarithmically. To investigate associations between PHLDA2 expres-
sion and parental body composition, fetal growth rates and infants
body composition, Pearson's and Spearman's correlation coefﬁcients
were calculated where appropriate. Differences in PHLDA2 expression
levels between different categories of maternal lifestyle were tested
by t-test or one-way analysis of variance. Neonatal anthropometric
measurements were adjusted for sex and gestational age and neona-
tal DXA measurements were adjusted for sex, gestational age and age
at DXA. As there was a question regarding sex differences in mRNA
levels between male and female placentas all mRNA data were
Table 2
Associations between placental PHLDA2 expression and neonatal parameters. N=102.
PHLDA2 relative mRNA levels
r P
Birth weight −0.02 0.88
Placental weight 0.01 0.92
Placental/birth weight ratio 0.02 0.87
Head circumference −0.03 0.78
Abdominal circumference 0.03 0.76
Crown heel length −0.10 0.30
Ponderal index 0.09 0.36
Mid upper arm circumference 0.07 0.48
Neonatal bone mineral content 0.07 0.49
Neonatal lean mass −0.03 0.79
Neonatal fat mass 0.07 0.46
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erated for femur length and abdominal circumference at 19 and
34 weeks. Royston models were ﬁtted to fetal measurements to
create z-scores for size and conditional growth rates [30]. To investi-
gate whether there were sex differences in the relationship between
PHLDA2 expression and the variables sex was included in regression
analyses as appropriate and where an interaction was found data
were analyzed separately by sex. Data were analyzed using Stata
version 11.0 (Statacorp, Texas, USA).
Results
Descriptive statistics
In this study, PHLDA2 gene expression was examined in the
placentas from 102 infants collected as part of the Southampton
Women's Survey. All were singleton, term deliveries (37 weeks gesta-
tion or greater). 53 of the infants were male and 49 were female.
Descriptive statistics are given in Table 1.
Relationships between neonatal parameters and term placental
expression of PHLDA2
Within this cohort of 102 infants, no association was found
between the placental expression level of PHLDA2 and birth weight,
placental weight or other neonatal anthropometric or body composi-
tion measurements at birth (Table 2).
Relationships between fetal growth parameters and term placental
expression of PHLDA2
Longitudinal fetal ultrasound data was available at both 19 and
34 weeks for 58 fetuses within the cohort of 102 infants. There were
no differences in the birth parameters between this subset of 58 preg-
nancies and the 43 pregnancies without full fetal scan data (data not
shown). A lower 19–34 week femur length z-score change (linear
growth velocity) was signiﬁcantly associated with higher term pla-
cental PHLDA2 mRNA levels (Table 3, Fig. 1). Fetal femur length was
not signiﬁcantly related to placental PHLDA2 expression at 19 weeks
of gestation but shorter fetal femur length at 34 weeks was associated
with higher term placental expression of PHLDA2 (r=0.35, P=0.01)
(Supplementary ﬁgure). This data suggests reduced femur growthTable 1
Pre-pregnant maternal and neonatal characteristics.
Mean or median
(SD or inter quartile range)
Number of
subjects
Maternal age (years) 30.9 (3.9) 102
Maternal height (cm) 162.3 (6.5) 101
Maternal body mass index
(kg/cm2)
25.2 (23.0–29.3) 101
Maternal mid upper arm
circumference (cm)
29.8 (27.2–32.7) 101
Maternal arm muscle area (cm2) 36.7 (31.1–43.5) 101
Offspring's birth weight (g) 3503 (453) 102
Placental weight (g) 470 (96) 101
Birth weight/Placental
weight ratio
7.5 (6.8–8.4) 101
Neonatal abdominal
circumference (cm)
31.7 (1.8) 102
Neonatal crown heel length
(cm)
49.7 (1.8) 102
Neonatal mid upper arm
circumference (cm)
11.6 (1.0) 102velocity late in gestation in infants with a higher expression level of
placental PHLDA2.
Placental expression of PHLDA2 was not related to fetal head cir-
cumference z-score at 19 weeks or 19–34 week fetal head circumfer-
ence growth velocity (Table 3). Fetal abdominal circumference z-
scores at 19 were not signiﬁcantly related to placental expression of
PHLDA2, but higher PHLDA2 expression was associated with a faster
fetal abdominal circumference growth velocity between 19 and
34 weeks (Table 3).
Relationships between placental expression of PHLDA2 and childhood
body composition at age 4 years
42 children in the study had DXA scans at age 4 years. There were
no signiﬁcant differences in the birth parameters collected for those
who had DXA and those who did not (data not shown). In the 22
male and 20 female children followed to 4 years, there was an inverse
relationship between placental PHLDA2 gene expression and bone
mineral content, bone area and bone mineral density determined
by DXA (Table 4). There were no signiﬁcant correlations between
either bone lean mass or fat mass and PHLDA2 expression when the
data was analyzed by the sex of the infant or independently of sex
(Table 4).
There were no signiﬁcant interactions between PHLDA2 mRNA
levels and sex with any fetal, neonatal or postnatal outcomes.
Parental parameters
Term placental PHLDA2 mRNA levels were not associated with
maternal parity primiparous vs multiparous (values are mean (SD),
1.1 (0.4) vs 1.0 (0.4), P=0.21), smoking (non-smoking 1.1 (0.3) vs
smoking 1.2 (0.6), P=0.18) or social class (social class I/II1.0 (0.3),Table 3
Associations between placental PHLDA2 expression and fetal parameters assessed by
ultrasound. N=59 at 19 weeks and 58 at 34 weeks. Signiﬁcant correlations are
highlighted in bold.
PHLDA2 relative
mRNA levels
r P
19 wk abdominal circumference z-score 0.01 0.93
34 wk abdominal circumference z-score 0.23 0.09
19–34 wk abdominal circumference growth velocity z-score 0.28 0.04
19 wk Head circumference z-score 0.15 0.27
34 wk head circumference z-score 0.005 0.97
19–34 wk head circumference growth velocity z-score −0.05 0.71
19 wk femur length z-score 0.13 0.34
34 wk femur length z-score −0.36 0.01
19–34 wk femur length growth velocity z-score −0.42 0.001
Fig. 1. Placental PHLDA2 relative mRNA levels at birth compared to a) birth weight (r=
−0.02, P=0.88) and b) 19–34 week fetal femur growth velocity (r=−0.42,
P=0.001) (Royston femur length Z score) [30].
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mothers who, at recruitment to the study, reported that they under-
took strenuous exercise compared to those who did not (1.2 (0.4)
vs 1.0 (0.3). P=0.02).
Term placental PHLDA2 mRNA levels were not associated with
mother's own birth weight (r=0.08, P=0.47), height (r=−0.05,
P=0.60), BMI (r=−0.16, P=0.11) or arm muscle area (r=−0.10,
P=0.33). There were no signiﬁcant interactions between term pla-
centa PHLDA2 mRNA levels and sex for any maternal anthropometricTable 4
Associations between placental PHLDA2 expression and body composition assessed by
DXA scan at age four years. N=42. Signiﬁcant correlations are highlighted in bold.
PHLDA2 relative mRNA levels
r P
Bone mineral content −0.38 0.01
Bone area −0.392 0.010
Bone mineral density −0.332 0.032
Volumetric bone mineral density −0.147 0.353
Lean mass −0.23 0.15
Fat mass −0.20 0.21
4 year height −0.122 0.369
4 year weight (kg) −0.043 0.805outcomes. A lower paternal birth weight was associated with higher
term placental PHLDA2 mRNA levels (R=−0.35, P=0.02).
Discussion
Our ﬁrst key ﬁnding was the negative correlation between linear
femur growth rate between 19 and 34 weeks of gestation and
PHLDA2 expression in the term placenta in both male and female
infants. A second ﬁnding was the negative correlation between bone
mineral content at age 4 years and PHLDA2 expression in the term
placenta.
Two independent studies have reported increased placental
PHLDA2 expression at term in growth restricted infants [15,16]. In a
third study, Apostolidou et al., reported a negative correlation be-
tween birth weight and placental PHLDA2 in 200 routine pregnancies
[17]. We did not identify a signiﬁcant negative trend between PHLDA2
expression in our 102 routine pregnancies which may suggest differ-
ences in the populations under study, differences in the way in which
these measurements were taken or differences in the methodologies,
for instance in our study we normalized to the geometric mean of
three housekeeping genes which had been shown to be stably
expressed in human placenta [28]. However, despite the lack of corre-
lation with birth weight, we did identify a statistically signiﬁcant neg-
ative correlation between PHLDA2 expression and linear growth
rate in the 58 infants who underwent ultrasound scanning at 19
and 34 weeks. There was also a weak negative correlation between
placental PHLDA2 and crown heel length at birth and also height at
age 4, both of which might be anticipated to have a relationship
with pre term femoral length. While these measurements did not
reach signiﬁcance, DXA data obtained at 4 years did reveal an inverse
correlation between placental PHLDA2 expression and bone mineral
content [31]. These data suggest that PHLDA2 may act to restrict
skeletal growth and this restricted growth in utero has post natal con-
sequences for skeletal integrity. As with birth weights, the lack of sig-
niﬁcant negative correlation of PHLDA2 expression with crown heel
length at birth and height at age 4 might be explained by the
imprecision of measurements taken on a single occasion over that
obtained from scan data. It may well be that with a larger cohort
these negative trends will achieve signiﬁcance.
We have previously reported a direct causative effect between
high PHLDA2 and late onset growth restriction in an animal model,
which we attributed to placental insufﬁciency [23,24]. Data from an
animal model employing bilateral uterine vessel ligation to mimic
placental insufﬁciency suggests a link between suboptimal fetal
growth and postnatal bone density [32]. PHLDA2may act speciﬁcally
to limit the transport of factors required for skeletal growth, for
example by limiting calcium transport. Alternatively, PHLDA2 may
indirectly affect calcium and bone metabolism through its role in
regulating the placental hormones [24] involved in driving the ma-
ternal adaptations to pregnancy, which include increased maternal
bone turnover. A third possibility is that PHLDA2 acts intrinsically
to limit bone growth. PHLDA2 is expressed in human chondrocytes
[33] and high expression of PHLDA2 has recently been reported in
hypertrophic mouse chondrocytes, as compared to proliferative/
resting chondrocytes [34]. Animal models will play an important
role in distinguishing between an intrinsic or extrinsic mechanism
for limiting skeletal growth. Whatever the mechanism turns out to
be, we have identiﬁed a potential role for PHLDA2 in restricting
early skeletal growth, which has post natal consequences for skeletal
integrity.
In contrast to the negative relationship with fetal femur growth,
PHLDA2was positively associated with change in abdominal circum-
ference from 19 to 34 weeks. There is much evidence to suggest that
different fetal compartments may be differentially regulated and
thus growth may not be concordant across these measurements.
Femur length may be taken as a proxy for linear growth of the
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ultrasound in late pregnancy); in contrast abdominal circumference
is a composite measure of liver size and thickness of subcutaneous
adipose tissue, potentially involving hormones such as IGF-1 and
leptin [35,36]. There is no reason to suppose therefore, that femur
length and abdominal circumference will relate in the same direc-
tion to a single regulator; indeed, we have previously demonstrated
differences in relationships between postnatal skeletal indices and
femur length compared with abdominal circumference growth in
utero [31]. These results support the notion that birth weight is a rel-
atively crude surrogate for fetal developmental and that a more de-
tailed measurement of individual markers of fetal growth may give
a more accurate assessment of the regulation of development in
utero.
A key question is what drives deregulated expression of PHLDA2?
In rodent models PHLDA2 responds to suboptimal in utero environ-
ments. Speciﬁcally, increased placental expression of PHLDA2 has
been reported in response to hypoxia during pregnancy, decreased
food consumption and maternal alcohol consumption [37,38]. In
this study, we noted that PHLDA2 expression was higher in mothers
who reported that they undertook strenuous exercise. A more exten-
sive study will be critical in determining the relevance of this obser-
vation. Lower paternal birth weight was also associated with higher
term placental PHLDA2 mRNA levels. PHLDA2 is imprinted and it is
the paternally-inherited copy that is silenced. There is currently no
evidence for full loss of imprinting of PHLDA2 in low birth weight
pregnancies [15,16] but increased expression could occur as a conse-
quence of the failure of the paternal genome to fully silence PHLDA2.
In which case, exploring the relationship between both maternal and
paternal lifestyles will be important.
Conclusion
In summary, higher expression of the placental growth regulator,
PHLDA2, was associated with lower fetal femur growth velocity be-
tween 19 and 34 weeks gestation in fetuses who are within a normal
birth weight range at birth. This suggests that the correct dosage of
PHLDA2 may be critical for optimal skeletal growth in the third tri-
mester of pregnancy. Alterations in bone mineral content suggest
that high placental PHLDA2 may have long-term consequences for
bone health. Different early life growth trajectories inﬂuence adult
health and the identiﬁcation of infants who have experienced sub-
optimal growth using a molecular marker rather than by birth weight
alone may be helpful in determining where to apply interventional
strategies to improve long-term health.
Supplementary materials related to this article can be found
online at doi:10.1016/j.bone.2011.11.003.
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